Epivios GmbH, a Düsseldorf, Germany-based developer of molecular diagnostic cancer tests, has received an undisclosed amount of funding.
The company intends to use the funding for the further development of its platform technology, advancing the first two assays and executing preliminary clinical validation studies, and expansion of both its laboratory and team.
Led by Nicole Groth and Dr Simeon Santourlidis, Epivios was founded in 2011 as a spin-off of the Heinrich Heine University of Düsseldorf. Its interdisciplinary team, comprising doctors and biologists, has been working since 2009 on innovative epigenetic procedures for cancer diagnosis. The company’s epigenetic platform technology includes a new kind of standardization tool that allows the comparison of samples with differing genetic constitution for the first time. Epivios´s new procedure also analyzes sequences, which spread across the entire genome.